IGC To Enter California Market With Hyalolex

IGC to Enter California Market with Hyalolex, its lead cannabis-based supplement for treating and managing Alzheimer’s patients.

MARYLAND: India Globalization Capital (IGC) has designated California as a priority market for Hyalolex, its lead cannabis-based supplement for treating and managing Alzheimer’s patients. “The cannabis market is showing explosive growth and we are aggressively moving forward with our vision of owning and marketing the leading brands for large medical indications such as Alzheimer’s, Parkinson’s, PTSD, Read the full article…

Puerto Rican Alzheimer’s Patients To Be First In U.S. To Obtain Cannabis-Based Relief

indoor grow

MARYLAND: Alzheimer’s patients in Puerto Rico will be the first in the United States to obtain Hyalolex, IGC’s proprietary cannabinoid based formulation aimed at relieving many of the symptoms of Alzheimer’s Disease, such as agitation, anxiety, sleep disorder, as well as caregiver distress, among others. Pursuant to an agreement between IGC and DaMa Pharmaceutical and its Read the full article…